publication

12 Jun 2025 ISB 2001 ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Multiple Myeloma Treatments Perro M. et al.…

12 Dec 2022 ISB 1442 Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma Jiang T.…

13 Apr 2022 ISB 1442 ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies Sammicheli S. et al. American Association for…